Plaque Psoriasis

This interview with Jayme Heim featured a discussion about some of the latest treatment-related news for atopic dermatitis and psoriasis.

The use of this scoring system twice-per-week may help patients to better manage their mild-to-moderate atopic dermatitis.

This new research demonstrated that when TNF-inhibition is effective, a shift to brodalumab treatment may be useful in suppression of psoriasis and improvement of patients’ quality of life.

Ashfaq Marghoob, MD, discusses his recent workshop presentation on dermoscopies for skin cancer.

The multi-center study led to several important findings, one of which being that history of biologic-use could be a factor of importance in secukinumab retention prediction.

This new analysis identified several major psoriasis risk factors, highlighting the idea that early management of such factors might help to decrease both the risk and severity of the skin disease.

The study met its primary endpoint of PASI improvement in the biosimilar and bio-originator cohorts.

This new research indicates a potentially-promising new way of addressing clinical management of prurigo nodularis.

This new data may need to be examined by health providers when they advise patients about treatment outcomes for increasing dosage, including those who could benefit from a higher dose of baricitinib.

In this interview segment, Dr. Lim further discussed findings from his team’s research into infrared radiation’s effects on the skin and the implications of these findings.

This interview featured a discussion with Dr. Lim on his team’s findings regarding the effects of infrared radiation on human skin.

Positive results from REMIX-1 and REMIX-2 on remilbrutinib could mean the beginning of a new class of chronic spontaneous urticaria therapy in about a decade.

This new data from the UK suggests possible opportunities for preventing anxiety and depression for those with eczema or psoriasis by addressing modifiable risk factors such as sleep.

This study’s findings demonstrate the necessity of risk factor identification for atopic-like dermatitis, as well as the importance of exploring alternative treatments for severe cases.

The data from this analysis indicates that for those with psoriasis, effective and long-term continuous control of the skin disease could diminish risk of CCVD risk.

The data from this new study may indicate home NBUVB treatment effectiveness and other benefits such as financial, convenience, and medical benefits.

In this interview with Dr. Gold, she describes her team’s recent findings from a phase 4 head-to-head study on risankizumab for psoriasis patients.

This new phase 4 data provides some valuable insights for healthcare professionals and those seeking to compare therapy options for psoriasis.

Brad Glick, DO, MPH; Mona Shahriari, MD, FAAD; Michael Cameron, MD, FAAD; and Linda Stein Gold, MD, comment on the future of plaque psoriasis treatment and share clinical pearls on the management of plaque psoriasis.

Expert dermatologists comment on the use of nonsteroidal topical therapies in the treatment of plaque psoriasis and how it has affected clinical practice.

Experts discuss the DERMIS clinical trials of roflumilast in the treatment of plaque psoriasis, highlighting its efficacy in the intertriginous areas.

This new data on factors which may inhibit access to dermatologic care indicates the potential value for policy-makers as well as educators to make changes to fill such gaps in care.

Mona Shahriari, MD, and Linda Stein Gold, MD, review the long-term safety and efficacy data of tapinarof as well as its use in clinical practice for the management of plaque psoriasis.

Experts in dermatology discuss recent advances in the plaque psoriasis treatment toolbox, highlighting the mechanism of action and data of tapinarof.

This new data indicates that while it is not a physically limiting disease, alopecia areata can substantially affect patients’ lives on an individual and national level.